These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 1491342)
1. Pharmacokinetic characterization and tissue distribution of the new glucocorticoid soft drug loteprednol etabonate in rats and dogs. Hochhaus G; Chen LS; Ratka A; Druzgala P; Howes J; Bodor N; Derendorf H J Pharm Sci; 1992 Dec; 81(12):1210-5. PubMed ID: 1491342 [TBL] [Abstract][Full Text] [Related]
2. Comments concerning "Pharmacokinetic characterization and tissue distribution of the new glucocorticoid soft drug loteprednol etabonate in rats and dogs". Sloan KB; Perrin JH J Pharm Sci; 1994 Jul; 83(7):1066-8. PubMed ID: 7965668 [No Abstract] [Full Text] [Related]
3. Metabolism, distribution, and transdermal permeation of a soft corticosteroid, loteprednol etabonate. Bodor N; Loftsson T; Wu WM Pharm Res; 1992 Oct; 9(10):1275-8. PubMed ID: 1448425 [TBL] [Abstract][Full Text] [Related]
4. Soft drugs--10. Blanching activity and receptor binding affinity of a new type of glucocorticoid: loteprednol etabonate. Druzgala P; Hochhaus G; Bodor N J Steroid Biochem Mol Biol; 1991 Feb; 38(2):149-54. PubMed ID: 2004037 [TBL] [Abstract][Full Text] [Related]
5. Soft drugs. 19. Pharmacokinetics, metabolism and excretion of a novel soft corticosteroid, loteprednol etabonate, in rats. Bodor N; Wu WM; Murakami T; Engel S Pharm Res; 1995 Jun; 12(6):875-9. PubMed ID: 7667193 [TBL] [Abstract][Full Text] [Related]
6. Ocular absorption and distribution of loteprednol etabonate, a soft steroid, in rabbit eyes. Druzgala P; Wu WM; Bodor N Curr Eye Res; 1991 Oct; 10(10):933-7. PubMed ID: 1959381 [TBL] [Abstract][Full Text] [Related]
7. Soft drugs. 18. Oral and rectal delivery of loteprednol etabonate, a novel soft corticosteroid, in rats--for safer treatment of gastrointestinal inflammation. Bodor N; Murakami T; Wu WM Pharm Res; 1995 Jun; 12(6):869-74. PubMed ID: 7667192 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and delta1-cortienic acid excretion after intravenous administration of prednisolone and loteprednol etabonate in rats. Wu WM; Tang Y; Buchwald P; Bodor N Pharmazie; 2010 Jun; 65(6):412-6. PubMed ID: 20614688 [TBL] [Abstract][Full Text] [Related]
9. Controlled evaluation of loteprednol etabonate and prednisolone acetate in the treatment of acute anterior uveitis. Loteprednol Etabonate US Uveitis Study Group. Am J Ophthalmol; 1999 May; 127(5):537-44. PubMed ID: 10334346 [TBL] [Abstract][Full Text] [Related]
10. Loteprednol etabonate ophthalmic suspension 0.5 %: efficacy and safety for postoperative anti-inflammatory use. Amon M; Busin M Int Ophthalmol; 2012 Oct; 32(5):507-17. PubMed ID: 22707339 [TBL] [Abstract][Full Text] [Related]
11. Permeability of a soft steroid, loteprednol etabonate, through an excised rabbit cornea. Reddy IK; Khan MA; Wu WM; Bodor NS J Ocul Pharmacol Ther; 1996; 12(2):159-67. PubMed ID: 8773932 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of the sequential metabolites of loteprednol etabonate in rats. Wu WM; Huang F; Lee Y; Buchwald P; Bodor N J Pharm Pharmacol; 2008 Mar; 60(3):291-7. PubMed ID: 18284808 [TBL] [Abstract][Full Text] [Related]
13. The conjunctival provocation test model of ocular allergy: utility for assessment of an ocular corticosteroid, loteprednol etabonate. Abelson M; Howes J; George M J Ocul Pharmacol Ther; 1998 Dec; 14(6):533-42. PubMed ID: 9867336 [TBL] [Abstract][Full Text] [Related]
14. Attenuation of ocular hypertension with the use of topical loteprednol etabonate 0.5% in steroid responders after corneal transplantation. Holland EJ; Djalilian AR; Sanderson JP Cornea; 2009 Dec; 28(10):1139-43. PubMed ID: 19770719 [TBL] [Abstract][Full Text] [Related]
15. A controlled evaluation of the efficacy and safety of loteprednol etabonate in the prophylactic treatment of seasonal allergic conjunctivitis. Loteprednol Allergic Conjunctivitis Study Group. Dell SJ; Shulman DG; Lowry GM; Howes J Am J Ophthalmol; 1997 Jun; 123(6):791-7. PubMed ID: 9535623 [TBL] [Abstract][Full Text] [Related]
16. Failure to detect systemic levels, and effects of loteprednol etabonate and its metabolite, PJ-91, following chronic ocular administration. Howes J; Novack GD J Ocul Pharmacol Ther; 1998 Apr; 14(2):153-8. PubMed ID: 9572541 [TBL] [Abstract][Full Text] [Related]
17. Intraocular pressure elevations with loteprednol etabonate: a retrospective chart review. Rajpal RK; Digby D; D'Aversa G; Mah F; Hollander DA; Conway T J Ocul Pharmacol Ther; 2011 Jun; 27(3):305-8. PubMed ID: 21574815 [TBL] [Abstract][Full Text] [Related]
18. Loteprednol etabonate 0.5% versus prednisolone acetate 1.0% for the treatment of inflammation after cataract surgery. Lane SS; Holland EJ J Cataract Refract Surg; 2013 Feb; 39(2):168-73. PubMed ID: 23232255 [TBL] [Abstract][Full Text] [Related]
19. Comparison of ophthalmic loteprednol etabonate and prednisolone acetate effects on adrenocortical response to ACTH in dogs. Kline KE; Walton SA; Specht AJ; Santoro D; Watson TJ; Eide ML; Opgenorth TA; Plummer CE Vet Ophthalmol; 2022 Nov; 25(6):468-475. PubMed ID: 35913421 [TBL] [Abstract][Full Text] [Related]
20. Prolonged exposure to loteprednol etabonate in human tear fluid and rabbit ocular tissues following topical ocular administration of Lotemax gel, 0.5%. Glogowski S; Lowe E; Siou-Mermet R; Ong T; Richardson M J Ocul Pharmacol Ther; 2014 Feb; 30(1):66-73. PubMed ID: 24325539 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]